Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;109(3):226-237.
doi: 10.1111/ejh.13790. Epub 2022 Jun 20.

Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies

Affiliations

Validation of patient-reported vaso-occlusive crisis day as an endpoint in sickle cell disease studies

Karin S Coyne et al. Eur J Haematol. 2022 Sep.

Abstract

Individuals with sickle cell disease (SCD) experience vaso-occlusive crises (VOC). Historically, VOC episodes have been assessed through medical utilization, thereby excluding events managed at home. In order to validate a daily patient-reported outcome for patients with SCD to accurately report their VOC status and experience of a pain crisis, a SCD Diary was included in Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS), a longitudinal, six-month, non-interventional study. The daily patient-completed diary included a description of SCD pain crisis, followed by questions on: pain crisis in the past 24 h (VOC Day question; respective response yes or no), worst pain, tiredness, and functioning. Thirty-five patients with SCD participated in ELIPSIS. Analyses were performed to validate the patient-reported VOC Day. Mean symptoms and functioning scores on the first or last VOC Day of a VOC Event were compared using t-tests with the mean of the three non-VOC Days before and after the event. Mean severity of symptoms and functioning scores on all VOC Days compared to all non-VOC Days were higher, with statistically significant mean differences between first/last VOC Days and respective three non-VOC Days (p's < .01). A subset of patients (n = 15) and caregivers (n = 9) were interviewed to evaluate their understanding of the SCD Diary questions. Nearly all confirmed that the pain crisis description accurately described the VOC experience, and participants expressed confidence differentiating SCD crisis pain from everyday pain. These results demonstrate patients can reliably report their experiences with VOC-related pain crises using the SCD Diary.

Keywords: ELIPSIS; daily diary; patient-report outcome; sickle cell disease; trial endpoint; vaso-occlusive.

PubMed Disclaimer

Conflict of interest statement

Christine L. Baker, Steven Arkin, and Debra D. Pittman are current employees and stockholders of Pfizer Inc. Sheryl Pease was an employee and stockholder of Pfizer Inc. at the time of manuscript development. Kathleen Wyrwich is a former Pfizer Inc. employee, and holds Pfizer stock and stock options, and Eli Lilly and Company stock. She is currently employed at Bristol Myers Squibb Company. Karin S. Coyne is a current employee of Evidera, and Brooke M. Currie was an employee of Evidera at the time of manuscript development. Dr. Coyne and Ms. Currie were paid consultants to Pfizer for this work and in connection with the development of this manuscript. Michael Callaghan is an employee of Central Michigan University and Children's Hospital of Michigan, and he is the medical director at Agios Pharmaceuticals.

Similar articles

Cited by

References

    1. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle‐cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77‐78. doi:10.1002/ajh.21570 - DOI - PubMed
    1. Weatherall DJ. The role of the inherited disorders of hemoglobin, the first “molecular diseases,” in the future of human genetics. Annu Rev Genomics Hum Genet. 2013;14:1‐24. doi:10.1146/annurev-genom-091212-153500 - DOI - PubMed
    1. Manwani D, Frenette PS. Vaso‐occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood. 2013;122(24):3892‐3898. doi:10.1182/blood-2013-05-498311 - DOI - PMC - PubMed
    1. Novelli EM, Gladwin MT. Crises in sickle cell disease. Chest. 2016;149(4):1082‐1093. doi:10.1016/j.chest.2015.12.016 - DOI - PMC - PubMed
    1. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79(1):17‐25. doi:10.1002/ajh.20336 - DOI - PubMed